TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05098223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to remove price promotions on unhealthy foods when online shopping
Description: Removal of price promotions on unhealthy foods
Study: NCT00240773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: 4 grams daily for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: 750 mg daily for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: 4 grams daily for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: 750 mg daily for six months
Study: NCT04444297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D Telemedicine
Description: A consultation performed with a 3D form of telemedicine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2D Telemedicine
Description: A consultation performed with 2D (standard) telemedicine
Study: NCT06523751

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trabeculopuncture
Description: Trabeculopuncture is performed with a Nd:YAG laser on the trabecular meshwork. Four punctures are created along the 180° nasal trabecular meshwork.
Study: NCT04828876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga practice
Description: Yoga basically consists of breathing techniques, asanas (postures) and relaxation phases.~Practiced Yoga Stages; 10 min. standing breathing exercise, 10 min. breathing exercise with seated asana, 10 min. lying down breathing exercise with asana, 20 min. sitting breathing exercise, 10 min. The session will be completed in 60 minutes, including deep relaxation stages by lying down. At the end of each session, patients' feedback about yoga practice will be received.
Study: NCT05074784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOPI Therapy
Description: Obtain IOPI reading at start of session, record the best of 3 readings as baseline strength. Calculate exercise resistance for session at 60% of baseline strength. Using the IOPI, participants will perform 24 sets of 5 repetition at anterior position, allowing for 30 secs rest in between sets.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tongue Depressor Traditional Intervention
Description: Using the tongue depressor, participants will be prompted to stick their tongue out as much as they can and to push hard against the tongue depressor for 10 seconds. They will be required to repeat this action 10 times, constituting one set. They will be asked to perform 3 sets, with 30 secs of rest between each set
Study: NCT05418920

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left-opening single-flap technique
Description: left-opening single-flap technique
Study: NCT06043349

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma and Topical 5% Minoxidil
Description: The intervention group will receive three PRP injections during three months in addition to the topical 5% minoxidil.
Study: NCT05418920

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double-flap group technique
Description: double-flap group technique
Study: NCT05717920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-629 (Open-label)
Description: ADX-629 (250 mg) administered twice daily for 90 days
Study: NCT06131203

Intervention type: DEVICE
Intervention: DeepView SnapShot Portable (DV-SSP)
Description: DV-SSP assistive imaging to collect observational data
Study: NCT04297761

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Filtered Air
Description: Ambient air will be filtered and used for control exposure.
Study: NCT05464277

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen to achieve assigned SpO2 (or FiO2) targets will be administered to study subjects. The treating clinician can alter oxygenation targets at any time if deemed necessary. The oxygenation goal will be based on SpO2 rather than arterial oxygen saturation (SaO2) or arterial pressure oxygen (PaO2) from arterial blood gases. However, PaO2 can be used instead in situations where the treating clinician considers that peripheral perfusion is poor or SpO2 readings are unreliable. Assigned SpO2 targets will apply to the study subjects for a total duration of 6 hours from intubation or until death or until transfer to the operating theater (whatever comes first).
Study: NCT04297761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wood Smoke
Description: Wood smoke is generated by smoldering dry white oak logs and the exposure level will be maintained at an average of 500 µg/m\^3 for 2 hours.
Study: NCT06401733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Aerobic and Resistance Exercise Program (IAREP)
Description: IAREP is a combined aerobic exercise and resistance training program that developed by qualified exercise professionals. It encompasses a 12-week exercise intervention, conducted in a blended mode which consists of face-to-face exercise, Zoom exercise, and pre-recorded video exercise.~Frequency: 3 times exercise per week. Intensity: moderate to vigorous exercise. Time of the exercise: 45-60 mins. Type of exercise: combined aerobic and resistance training.~Warm-up: aerobic workout with dynamic stretch (for targeted muscles). Aerobic exercise: each session encompasses 5 exercise. Resistance training: each session encompasses 4 exercise, 2 upper body exercise and 2 lower body exercise.~Cool-down: relax targeted muscles.
Study: NCT05538130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07799544
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07799544
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07799544
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07799544
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07799933
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07799933
Description: Tablet
Study: NCT06043349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical 5% Minoxidil
Description: The intervention group will receive topical 5% minoxidil as standard therapy for male androgenetic alopecia.
Study: NCT04686487

Intervention type: PROCEDURE
Group type: OTHER
Intervention: stereotactic ablative radiotherapy
Description: stereotactic ablative radiotherapy by targeting high energy heavy ion beams at a specific area of the body
Study: NCT03663153

Intervention type: OTHER
Intervention: SEMA4C high value follow-up group
Description: Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.

Intervention type: OTHER
Intervention: SEMA4C low value follow-up group
Description: Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
Study: NCT04648501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task training
Description: Dual-task (CIBT- experimental) group participants will receive 10 minutes of warm up, 40 minutes of CIBT training and 10 minutes of cool down exercises. CIBT program includes performing four types of cognitive tasks during sit to stand, standing with feet apart, one leg, tandem standing, multidirectional reaching, stair climbing and walking (10 metres) tasks. The four cognitive tasks will include: counting backwards by subtracting 4 numbers (for mental tracking ), naming fruits, vegetables, or animals (for working memory), auditory cues for performing activities, example, perform heel raise when you hear the alphabet H (for improving attention and auditory discrimination), short story telling (for verbal fluency). In addition, falls prevention strategies will be taught.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual-task training
Description: Dual-task (CIBT- experimental) group participants will receive 10 minutes of warm up, 40 minutes of CIBT training and 10 minutes of cool down exercises. CIBT program includes performing four types of cognitive tasks during sit to stand, standing with feet apart, one leg, tandem standing, multidirectional reaching, stair climbing and walking (10 metres) tasks. The four cognitive tasks will include: counting backwards by subtracting 4 numbers (for mental tracking ), naming fruits, vegetables, or animals (for working memory), auditory cues for performing activities, example, perform heel raise when you hear the alphabet H (for improving attention and auditory discrimination), short story telling (for verbal fluency). In addition, falls prevention strategies will be taught.
Study: NCT04508764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Families Accelerating Cascade Testing Toolkit
Description: -Online family history assessment, video of Siteman Cancer Center genetic counselors, physicians and patients highlighting the importance of cascade genetic testing, reviewing and receiving a family letter and gene information sheet, reviewing websites/online resources, and offering a family visit with a genetic counselor
Study: NCT05538130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07799933
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: Capsule
Study: NCT05706675

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical periodontal therapy
Description: Manual root planning+Ultrasonic subgingival debridement
Study: NCT05993871

Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve Conduction Study
Description: Routine Nerve Conduction Study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve Conduction Study
Description: Routine Nerve Conduction Study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve Conduction Study
Description: Routine Nerve Conduction Study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Small fiber electrodiagnostic tests
Description: R-R interval analysis, Cutaneous Silent Period and Sympathetic Skin Response.

Intervention type: DIAGNOSTIC_TEST
Intervention: Small fiber electrodiagnostic tests
Description: R-R interval analysis, Cutaneous Silent Period and Sympathetic Skin Response.

Intervention type: DIAGNOSTIC_TEST
Intervention: Small fiber electrodiagnostic tests
Description: R-R interval analysis, Cutaneous Silent Period and Sympathetic Skin Response.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve Ultrasound
Description: Bilateral vagal, left median, right ulnar, left tibial and right sural nerves ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve Ultrasound
Description: Bilateral vagal, left median, right ulnar, left tibial and right sural nerves ultrasound.
Study: NCT04262427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50mg
Description: cytotoxic chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]
Description: potent humanized immunoglobulin (Ig) G4 monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor
Study: NCT06207227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VITA AV Clinical System
Description: The VITA AV Clinical System that works on the principle of negative pressure suction to the vaginal wall to treat VA, based on the idea of the clinical application in wound healing which is intended to elicit improvements in the rate of angiogenesis, moisture and HA production post-treatment. It is believed that the VITA AV Clinical System will provide a more effective treatment by improving the underlying cellular deficiencies associated with VA.
Study: NCT05738616

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib combined with TACE and Camrelizumab
Description: Once subjects have signed the informed consent and passed screening, they will be randomized in a 1:1 ratio to either the experimental arm (lenvatinib combined with TACE and camrelizumab) or the control arm (lenvatinib combined with TACE).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lenvatinib combined with TACE and Camrelizumab
Description: Once subjects have signed the informed consent and passed screening, they will be randomized in a 1:1 ratio to either the experimental arm (lenvatinib combined with TACE and camrelizumab) or the control arm (lenvatinib combined with TACE).
Study: NCT05993871

Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve Ultrasound
Description: Bilateral vagal, left median, right ulnar, left tibial and right sural nerves ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Biopsy
Description: distal leg 3mm punch skin biopsy

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Biopsy
Description: distal leg 3mm punch skin biopsy
Study: NCT05420012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat
Description: A starting dose of vericiguat 2.5 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Subjects will be up-titrated in a blinded fashion to 5 mg and then to the target dose of 10 mg of vericiguat or matching placebo using titration criteria based on mean systolic blood pressure(SBP) evaluation and clinical symptoms at 2 week intervals. Titration to 10 mg in subjects who have not yet reached the target dose is intended at every visit/phone call throughout the study duration based on mean SBP measurement and safety considerations, at the discretion of the investigator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A starting dose of vericiguat 2.5 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Subjects will be up-titrated in a blinded fashion to 5 mg and then to the target dose of 10 mg of vericiguat or matching placebo using titration criteria based on mean systolic blood pressure(SBP) evaluation and clinical symptoms at 2 week intervals. Titration to 10 mg in subjects who have not yet reached the target dose is intended at every visit/phone call throughout the study duration based on mean SBP measurement and safety considerations, at the discretion of the investigator.
Study: NCT05980026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral omega-3 fatty acids supplementation
Description: oral omega-3 fatty acids supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in placebo group received placebo that were similar in appearance to omega 3 fatty acids and the administered dose was as the same schedule as omega 3 fatty acids.
Study: NCT05657977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nonpharmacologic intervention (swaddling)
Description: Swaddling method;The newborn will be placed on a square fabric blanket in the flexion and abduction position and will be loosely swaddled with a blanket.
Study: NCT04859127

Intervention type: OTHER
Intervention: effects of neck pain
Description: Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology, questioning of the status of the inquiry Neck Disability Survey, stars in the evaluation of balance dynamic balance test, stand on one leg Test in the evaluation of static balance, dynamic balance and physical performance Term rise and walk test, gait speed for the assessment of the 10-meter walk test and dual-task for the evaluation of the motor-the motor and motor-Cognitive dual-task will be used for the evaluation.

Intervention type: OTHER
Intervention: effects of neck pain
Description: Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology, questioning of the status of the inquiry Neck Disability Survey, stars in the evaluation of balance dynamic balance test, stand on one leg Test in the evaluation of static balance, dynamic balance and physical performance Term rise and walk test, gait speed for the assessment of the 10-meter walk test and dual-task for the evaluation of the motor-the motor and motor-Cognitive dual-task will be used for the evaluation.
Study: NCT05385705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide at a single dose of 600mg/m2 IV between days -5 and -3 before NK cell infusion for preconditioning the tumoral microenvironment by reducing the levels of lymphocyte T regulators (Tregs FOXP3+, CD3+, CD4+, CD25+).
Study: NCT05919823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline and Trospium Chloride Capsules
Description: Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules
Study: NCT06021223

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chicken extract supplement (high-dose)
Description: 140ml of chicken extract supplement (high-dose) to be consumed daily for 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chicken extract supplement (low-dose)
Description: 140ml of chicken extract supplement (low-dose) to be consumed daily for 2 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 140ml of placebo to be consumed daily for 2 weeks
Study: NCT05385705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab at a dose of 8mg/kg IV for the loading dose on Day 1, and 6mg/kg IV for the maintenance dose every 3 weeks (Q3W).
Study: NCT05259540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: compound kushen injection combined with pabolizumab
Description: compound kushen injection 20ml/day and pabolizumab 200mg/21 days, both drugs are given intravenously
Study: NCT05999552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye exercises
Description: The treatment will be applied in three sessions a week for eight weeks and each session will be approximately 20 minutes. Individuals will do each exercise shown at home as a home program on other days (days when the physiotherapist does not perform the exercise by video call).
Study: NCT05848050

Intervention type: PROCEDURE
Group type: OTHER
Intervention: biological samples (blood test and lumbar puncture)
Description: On the day of excision of the cerebral metastasis, additional biological samples (blood test and lumbar puncture) will be taken in the operating room.~A biological sample of the tumor tissue (brain metastases of a solid cancer with contrast uptake of at least 1 cm accessible to surgical excision) will also be taken and preserved by freezing, in accordance with current practice and after obtaining their written agreement. .~Biological samples (liquid biopsies and tumour) from patients who have explicitly expressed their consent will be kept after the end of the research as part of a biobank in order to be able to carry out any additional analyses.
Study: NCT06471517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatosensory feedback
Description: Performing different mobility tasks in 10 separate sessions while the device is providing or not somatotopic sensations through non-invasive electrical stimulation. Benefits connected to the stimulation of sensory nerves will be assessed.
Study: NCT05549453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexstim SNBT use
Description: Active device use
Study: NCT05670197

Intervention type: OTHER
Intervention: No intervention. Participants will take part in a qualitative interview
Description: No intervention. Participants will take part in a one-off, audio-recorded qualitative interview, lasting up to 60 minutes. The interviewer will ask about participants' views on complex digital remote monitoring.

Intervention type: OTHER
Intervention: No intervention. Participants will take part in a qualitative interview
Description: No intervention. Participants will take part in a one-off, audio-recorded qualitative interview, lasting up to 60 minutes. The interviewer will ask about participants' views on complex digital remote monitoring.
Study: NCT06184724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation Package for CGA
Description: The Implementation Package will include a set of implementation strategies to improve the use of CGA before surgery. These strategies will be applied at the clinic-level to help increase the reach and adoption of the CGA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Clinical Care
Description: Routine care may or may not include the use of the CGA before surgery. The use of CGA in clinical care is up to the medical and surgical healthcare providers.
Study: NCT06177912

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Study: NCT05385705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab at a dose of 840mg IV for the loading dose on Day 1, and 420 mg IV for the maintenance dose every 3 weeks (Q3W).
Study: NCT06404684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: se above